Skip to main content
RARE $17.53 -1.16%
RARE logo
RARE · Ultragenyx Pharmaceutical Inc.
Track RARE — free
$17.53 -0.21 (-1.16%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.81B
Shares
101.92M
Volume · Nov 19 1.01M Avg daily vol (3M) 4.67M
All webcasts

Earnings call · FY2026 Q2

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call

Concluded Aug 4, 2026
Aug 4, 2026
Period
FY2026 Q2
Runtime
—
Sources
3 artifacts
Revenue $214.00M +28.1% YoY
Diluted EPS -$0.90
Net income -$92.00M
Open full screen Slides 8 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-Q stay in one workspace.

Angelman syndrome Phase III (GTX102) endpoints and design 10 DTX401 regulatory progress 5 UX143 (citruzumab) for osteogenesis imperfecta 5 GTS1-2 Phase III ASPIRE readout 4 Long-term GTX102 durability and safety 4 UX111 regulatory progress 4

Management tone

Positive

Net tone +35 · moderate hedging

Grounding quotes
  • “The Phase I to open-label single-arm data demonstrates substantial clinical benefit, well beyond what might be considered with placebo”
  • “While neither study hit statistical significance for the primary endpoints of annualized fracture reductions, we did see clear signals of biologic activity”
  • “We will see the data when they come.”

Forward guidance

3 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Aug 4, 2026.

Metric Guided
Total revenue Maintained
full year 2026
$730M – $760M
Crysvita revenue Maintained
full year 2026
$500M – $520M
Dojolvi revenue Maintained
full year 2026
$100M – $110M

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Product$112.00M +38.3% YoY
Royalty$102.00M +18.6% YoY
Full-screen source Call document